Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])
Authors:
Open Access
- 16 September 2022
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 124, 187-189
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic pneumonia following Sinovac/CoronaVac vaccinationEuropean Annals of Allergy and Clinical Immunology, 2023
- Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®)Medical Gas Research, 2022
- Three cases of drug‐induced hypersensitivity syndrome associated with mRNA‐based coronavirus disease 2019 vaccinesThe Journal of Dermatology, 2022
- Eosinophilic Granulomatosis With Polyangiitis Diagnosed in an Elderly Female After the Second Dose of mRNA Vaccine Against COVID-19Cureus, 2022
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsNew England Journal of Medicine, 2021
- Recent advances and developments in COVID‐19 in the context of allergic diseasesClinical and Translational Allergy, 2021
- COVID vaccination and asthma exacerbation: might there be a link?International Journal of Infectious Diseases, 2021
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Asthma exacerbations {middle dot} 2: AetiologyThorax, 2006
- Eosinophils, bronchial hyperreactivity and late‐phase asthmatic reactionsClinical & Experimental Allergy, 1985